Clinical Trial Update: Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis [Phase 4]

View source ↗

Summary

Phase 4 trial investigating the safety and efficacy of olopatadine nasal spray 0.6% and azelastine nasal spray (137 mcg) in vasomotor rhinitis; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vasomotor Rhinitis

Drugs mentioned

• Azelastine nasal spray 137 mcg (azelastine)
• Olopatadine nasal spray 0.6% (olopatadine)

Snippet

Sponsor: Alcon Research | Conditions: Vasomotor Rhinitis | Phase 4 | Status: COMPLETED | Results posted: 2011-05-10